Abstract: Provided are methods of preventing, delaying, mitigating, reducing and/or inhibiting alpha-synuclein aggregates in the brains of a subject at risk of developing or suffering a cognitive disease associated with, caused and/or mediated at least in part by alpha-synuclein aggregates, for example, Parkinson's Disease or Dementia with Lewy Bodies (DLB).

Abstract: A seatback includes a pressure-receiving member and a drive mechanism. The pressure-receiving member includes a first pressure-receiving portion configured to support a lumbar region of an occupant, and a second pressure-receiving portion joined to an upper part of the first pressure-receiving portion and configured to support a back of the occupant in cooperation with the first pressure-receiving portion. The drive mechanism is configured to displace the pressure-receiving member between a support position and a non-support position, which is a position rearward of the support position. The pressure-receiving member is configured, when in the support position, to be bent at a joining portion where the first pressure-receiving portion and the second pressure-receiving portion are joined together to become convex toward a seat front side.

Abstract: The present invention is to provide a preventive or therapeutic agent for a neurodegenerative disease or a cognitive dysfunction, containing a compound represented by a following formula (I) or a pharmacologically acceptable salt thereof as an active ingredient.

Abstract: Provided is a novel compound having rapid and long-lasting therapeutic effects on diseases exhibiting depressive symptoms. Specifically, provided are an agent for prevention and/or treatment of a depressive symptom, consisting of R(?)-ketamine or a pharmacologically acceptable salt thereof, and a pharmaceutical composition for prevention and/or treatment of a depressive symptom, comprising R(?)-ketamine or a pharmacologically acceptable salt thereof in an effective amount for reducing a depressive symptom, and being substantially free of S(+)-ketamine, and a pharmacologically acceptable salt thereof.

Abstract: A terminal receives a download notification of a profile configured in an embedded subscriber identification module from a push server. The terminal accesses the download destination in accordance with the download notification and receives the profile. The terminal configures the profile to the embedded subscriber identification module. In other aspects, a communication system, a method for controlling a terminal, and a method for controlling a communication system are also disclosed.

Abstract: A winding core includes a winding core portion extending in a length direction; and first and second flange portions respectively provided at first and second end portions of the winding core portion in the length direction, and each having a bottom surface, a top surface on a side opposite to the bottom surface, an inner end surface facing the winding core portion side, and an outer end surface on a side opposite to the inner end surface, with a convex step portion on the top surface side of the outer end surface. The winding core portion has an upper surface facing substantially the same direction as a direction in which the top surface faces. A first straight line passing through the top surface and a second straight line passing through the upper surface intersect outside the outer end surface at an angle of from 0.3 degrees to 5 degrees.

Abstract: This preventive or therapeutic agent for inflammatory diseases or bone diseases, and this pharmaceutical composition for preventing or treating inflammatory diseases or bone diseases include, as effective components, a compound represented by formula (1) or a pharmaceutically acceptable salt thereof. [In formula (1), X is a hydrogen atom, a halogen atom, or a C1-C10 alkyl group that may be substituted; R1 is a C1-C10 alkyl group that may be substituted, a C1-C10 alkenyl group that may be substituted, or a C6-C14 aryl group that may be substituted; and one or more hydrogen atoms may be substituted with deuterium atoms.

Abstract: Provided herein are methods of preventing, reducing, ameliorating, mitigating, inhibiting, treating and/or reversing a neurodevelopmental disorder related to prenatal maternal immune activation in an individual in need thereof comprising administering to said individual an agent that increases the level of epoxy-fatty acids wherein said individual experienced maternal immune activation one or more times during gestation. Also provided herein are methods of preventing, reducing, ameliorating, mitigating, inhibiting treating and/or reversing schizophrenia or autism spectrum disorder an individual comprising administering to said individual an agent that increases the level of epoxy-fatty acids.

Abstract: The control unit includes a retrieval target article identification unit configured to identify a retrieval target article from among the articles stored in the storage unit on the basis of retrieval information indicating a retrieval completion state, a reverse sequential operation calculation unit configured to calculate a reverse sequential operation when it is assumed that the retrieval target article is moved to the storage position in the storage unit in a reverse sequence from the retrieval completion state, and a retrieval operation calculation unit configured to calculate a retrieval operation in which the retrieval target article is moved from the storage position in the storage unit and is in the retrieval completion state by reproducing the reverse sequential operation in reverse.

Abstract: This air pump device is provided with: an electric pump unit including a pump mechanism and a motor; a case; and a vibration-proof member. The pump mechanism and the motor are arranged side by side in the axial direction of the motor. The pump mechanism has an inlet and an outlet at an end in the axial direction on the opposite side of the motor. The case has a first wall and a second wall which are located on opposite sides in the axial direction of the motor and which face the electric pump unit. The vibration-proof member is provided with: a first axial vibration-proof unit interposed between the electric pump unit and the first wall; and a second axial vibration-proof unit interposed between the electric pump unit and the second wall. The first axial vibration-proof unit covers the inlet.

Abstract: This invention provides methods for preventing, mitigating, ameliorating and/or controlling psychiatric disorders, including depression, major depression, bipolar disorder, schizophrenia and substance abuse (including addiction and dependence) by administration of an agent that increases epoxy-fatty acids (e.g., an inhibitor of soluble epoxide hydrolase), as sole active agent or in combination with another agent (e.g., an antidepressant, an antipsychotic, an anxiolytic). When co-administered in combination with another agent, one or both agent may be administered at a subtherapeutic dose.

Abstract: The present invention provides a prophylactic or therapeutic agent for neurodevelopmental disorder that comprises a compound represented by formula (I) or a pharmacologically acceptable salt thereof as an active ingredient.

Abstract: Provided is a novel compound having rapid and long-lasting therapeutic effects on diseases exhibiting depressive symptoms. Specifically, provided are an agent for prevention and/or treatment of a depressive symptom, consisting of R(?)-ketamine or a pharmacologically acceptable salt thereof, and a pharmaceutical composition for prevention and/or treatment of a depressive symptom, comprising R(?)-ketamine or a pharmacologically acceptable salt thereof in an effective amount for reducing a depressive symptom, and being substantially free of S(+)-ketamine, and a pharmacologically acceptable salt thereof.

Abstract: A seat device includes a holding member that holds an air tube and is located below a seat cushion. The holding member includes a base wall that defines a holding surface for the air tube, a locking portion that locks air tubes routed along the holding surface on the base wall, and a side wall extending in a routing direction of each of the air tubes.

Abstract: Provided is a novel compound having rapid and long-lasting therapeutic effects on diseases exhibiting depressive symptoms. Specifically, provided are an agent for prevention and/or treatment of a depressive symptom, consisting of R(?)-ketamine or a pharmacologically acceptable salt thereof, and a pharmaceutical composition for prevention and/or treatment of a depressive symptom, comprising R(?)-ketamine or a pharmacologically acceptable salt thereof in an effective amount for reducing a depressive symptom, and being substantially free of S(+)-ketamine, and a pharmacologically acceptable salt thereof.

Abstract: A radial tire for an aircraft, the radial tire having a rim diameter of 20 inches or less includes a pair of bead portions; a pair of sidewall portions extending outward from the bead portions in a substantially radial direction; a tread portion that couples together respective radial outer ends of the sidewall portions; a toroidal carcass layer reinforcing a portion between bead cores embedded in the bead portions; a belt layer and a tread that are sequentially laminated on an outer side of the carcass layer in the radial direction, wherein a value M obtained by dividing a tire external diameter D by a distance L between bead heels of the bead portions is in a range of from 4.1 to 5.4.

Abstract: Provided is a seatback rotating device used for a vehicle seat. The seatback rotating device includes an electric motor, an action mechanism, a rotor, and an abutment target portion. In the seatback rotating device, when s seatback of the vehicle sat is placed in a first standing position, the rotor is positioned in a standby state that creates a gap between a first protrusion and the abutment target portion and a gap between a second protrusion and the abutment target portion, the first protrusion and the second protrusion being provided to the rotor. In the standby state, a gap length from the first protrusion to the abutment target portion is small relative to a gap length from the second protrusion to the abutment target portion.

Abstract: Provided is a seatback rotating device. The seatback rotating device includes an electric motor and an application mechanism. The electric motor generates a rotational force that is used to rotationally displace a seatback of a vehicle seat. The application mechanism enables application of the rotational force to the seatback. The application mechanism has a configuration that enables the seatback to be self-rotatable with gravity applied to the seatback in response to the rotational force being applied to the seatback.

Abstract: A seat device includes a holding member that holds an air tube and is located below a seat cushion. The holding member includes a base wall that defines a holding surface for the air tube, a locking portion that locks air tubes routed along the holding surface on the base wall, and a side wall extending in a routing direction of each of the air tubes.

Abstract: This invention provides methods for preventing, mitigating, ameliorating and/or controlling psychiatric disorders, including depression, major depression, bipolar disorder, schizophrenia and substance abuse (including addiction and dependence) by administration of an agent that increases epoxy-fatty acids (e.g., an inhibitor of soluble epoxide hydrolase), as sole active agent or in combination with another agent (e.g., an antidepressant, an antipsychotic, an anxiolytic). When co-administered in combination with another agent, one or both agent may be administered at a subtherapeutic dose.